Forte Biosciences Inc. (FBRX)
Forte Biosciences Statistics
Share Statistics
Forte Biosciences has 6.58M shares outstanding. The number of shares has increased by -82.46% in one year.
Shares Outstanding | 6.58M |
Shares Change (YoY) | -82.46% |
Shares Change (QoQ) | 337.32% |
Owned by Institutions (%) | 41.38% |
Shares Floating | 5.32M |
Failed to Deliver (FTD) Shares | 595 |
FTD / Avg. Volume | 1.51% |
Short Selling Information
The latest short interest is 982, so 0.02% of the outstanding shares have been sold short.
Short Interest | 982 |
Short % of Shares Out | 0.02% |
Short % of Float | 0.02% |
Short Ratio (days to cover) | 0.09 |
Valuation Ratios
The PE ratio is -1.87 and the forward PE ratio is -4.19. Forte Biosciences's PEG ratio is 0.04.
PE Ratio | -1.87 |
Forward PE | -4.19 |
PS Ratio | 0 |
Forward PS | 1.8 |
PB Ratio | 1.26 |
P/FCF Ratio | -2.15 |
PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Forte Biosciences.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.76, with a Debt / Equity ratio of 0.
Current Ratio | 6.76 |
Quick Ratio | 6.76 |
Debt / Equity | 0 |
Debt / EBITDA | 0 |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-2.53M |
Employee Count | 14 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -68.77% in the last 52 weeks. The beta is 2.86, so Forte Biosciences's price volatility has been higher than the market average.
Beta | 2.86 |
52-Week Price Change | -68.77% |
50-Day Moving Average | 9.03 |
200-Day Moving Average | 11.17 |
Relative Strength Index (RSI) | 37.79 |
Average Volume (20 Days) | 39.51K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -36.6M |
Net Income | -35.48M |
EBITDA | -36.6M |
EBIT | n/a |
Earnings Per Share (EPS) | -12.17 |
Balance Sheet
The company has 22.24M in cash and 0 in debt, giving a net cash position of 22.24M.
Cash & Cash Equivalents | 22.24M |
Total Debt | 0 |
Net Cash | 22.24M |
Retained Earnings | -154M |
Total Assets | 61.56M |
Working Capital | 52.27M |
Cash Flow
In the last 12 months, operating cash flow was -30.75M and capital expenditures -37K, giving a free cash flow of -30.78M.
Operating Cash Flow | -30.75M |
Capital Expenditures | -37K |
Free Cash Flow | -30.78M |
FCF Per Share | -10.56 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
FBRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for FBRX is $80.5, which is 1312.3% higher than the current price. The consensus rating is "Buy".
Price Target | $80.5 |
Price Target Difference | 1312.3% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Stock Splits
The last stock split was on Aug 28, 2024. It was a backward split with a ratio of 1:25.
Last Split Date | Aug 28, 2024 |
Split Type | backward |
Split Ratio | 1:25 |
Scores
Altman Z-Score | -2.03 |
Piotroski F-Score | 1 |